News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Features COVID-19’s Enduring Impact on the Heart? Some Clues and Predictions Shelley Wood July 20, 2020
News Features Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis? Michael O'Riordan February 01, 2019
News Features The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine Shelley Wood October 22, 2018
News Features COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict Todd Neale September 15, 2017